menu
    • menu
    [{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Sesen Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Vicineum","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Qilu Pharmaceutical \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Quantum Genomics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Firibastat","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Qilu Pharmaceutical \/ qilu pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ qilu pharmaceutical"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Cend Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"CEND-1","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Qilu Pharmaceutical \/ Cend Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Qilu Pharmaceutical \/ Cend Therapeutics"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Peptron","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"PAb001-ADC","moa":"MUC1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qilu Pharmaceutical \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Qilu Pharmaceutical \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"ECI Pharmaceuticals LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qilu Pharmaceutical \/ ECI Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Qilu Pharmaceutical \/ ECI Pharmaceuticals"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Arbutus Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"GalNAc-RNAi","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Qilu Pharmaceutical","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.29999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qilu Pharmaceutical \/ Qilu Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Qilu Pharmaceutical \/ Qilu Pharmaceuticals"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Iparomlimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Qilu Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Qilu Pharmaceutical \/ Qilu Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Qilu Pharmaceutical \/ Qilu Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Qilu Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Qilu Pharmaceutical \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Qilu Pharmaceutical

    Menu

    Qilu Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certepetide,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Lisata Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lisata And Qilu Pharmaceutical Announce First Patient Treated In Qilu's Phase 2 Of LSTA1

                            Details : LSTA1 (certepetide) is under investigation in combination with Gemcitabine and Nab-paclitaxel for treating patients with metastatic pancreatic ductal adenocarcinoma and metastatic pancreatic cancer.

                            Brand Name : LSTA1

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            April 23, 2024

                            Lead Product(s) : Certepetide,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Lisata Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iparomlimab,Tuvonralimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qilu Pharmaceutical Announces the Latest Results from its Clinical Study on QL1706, in Combination with Chemot...

                            Details : QL1706 (iparomlimab and tuvonralimab) in combination with chemotherapy, with or without bevacizumab, as a first-line treatment of recurrent or metastatic cervical cancer (r/mCC).

                            Brand Name : QL1706

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 25, 2023

                            Lead Product(s) : Iparomlimab,Tuvonralimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paliperidone Palmitate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qilu Launches First Generic Version of Invega Sustenna® in China

                            Details : Invega Sustenna is a monthly long-acting atypical antipsychotic medication used to treat schizophrenia and schizoaffective disorder.

                            Brand Name : Invega Sustenna-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 12, 2023

                            Lead Product(s) : Paliperidone Palmitate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GalNAc-RNAi,Pegylated Interferon alpha 2a

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Arbutus Biopharma

                            Deal Size : $300.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Devel...

                            Details : Under the terms of the agreement, Qilu Pharmaceutical will gain the rights for the development and commercialization of AB-729 for the treatment or prevention of hepatitis B in mainland China, Hong Kong, Macau and Taiwan.

                            Brand Name : AB-729

                            Molecule Type : Large molecule

                            Upfront Cash : $40.0 million

                            December 13, 2021

                            Lead Product(s) : GalNAc-RNAi,Pegylated Interferon alpha 2a

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Arbutus Biopharma

                            Deal Size : $300.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tadalafil

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : ECI Pharmaceuticals LLC

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ECI Pharmaceuticals LLC Signs Agreement to Be Exclusive U.S. Distributor of Generic Cialis®

                            Details : Cialis®, and the generic equivalent Tadalafil, is in a class of medications called phosphodiesterase (PDE) inhibitors. Tadalafil is used to treat erectile dysfunction and the symptoms of benign prostatic hyperplasia (BPH; an enlarged prostate).

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 10, 2021

                            Lead Product(s) : Tadalafil

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : ECI Pharmaceuticals LLC

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PAb001-ADC

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Peptron

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC

                            Details : Under the terms of the agreement, Peptron grants Qilu an exclusive global right and license to develop, manufacture, sell, and commercialize PAb001-ADC for the treatment of cancers.

                            Brand Name : PAb001-ADC

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 16, 2021

                            Lead Product(s) : PAb001-ADC

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Peptron

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CEND-1,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Cend Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz®

                            Details : Cend presented favorable clinical results at the European Society for Molecular Oncology (ESMO) meeting September 2020 and is advancing into Phase 2 clinical trials in pancreatic cancer with CEND-1 in combination with gemcitabine and nab-paclitaxel.

                            Brand Name : CEND-1

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            February 16, 2021

                            Lead Product(s) : CEND-1,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Cend Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Firibastat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : Quantum Genomics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical

                            Details : Under the terms of the agreement, Qilu Pharmaceutical will receive the exclusive rights to market firibastat for the treatment of difficult-to-treat / resistant hypertension in China, including Hong Kong and Macau.

                            Brand Name : QGC001

                            Molecule Type : Small molecule

                            Upfront Cash : $50.0 million

                            October 19, 2020

                            Lead Product(s) : Firibastat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : Quantum Genomics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Qilu Pharmaceutical

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vicineum

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Sesen Bio

                            Deal Size : $35.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sesen Bio Signs Exclusive License Agreement with Qilu Pharmaceutical for the Development and Commercialization...

                            Details : Companies have entered into an exclusive licensing agreement for the manufacture, development and commercialization of Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer and other types of cancer in China, Hong Kong, Macau ...

                            Brand Name : VB4-845

                            Molecule Type : Large molecule

                            Upfront Cash : $12.0 million

                            July 31, 2020

                            Lead Product(s) : Vicineum

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Sesen Bio

                            Deal Size : $35.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth